
Palatin Technologies (NASDAQ:PTN – Free Report) – Stock analysts at HC Wainwright issued their FY2028 earnings estimates for Palatin Technologies in a research report issued on Tuesday, November 17th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($1.72) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Palatin Technologies’ current full-year earnings is ($1.50) per share.
Palatin Technologies (NASDAQ:PTN – Get Free Report) last released its earnings results on Monday, September 28th. The company reported ($1.11) earnings per share for the quarter. The business had revenue of $0.30 million for the quarter. Palatin Technologies had a negative net margin of 385.38% and a negative return on equity of 189.04%.
Get Our Latest Stock Report on Palatin Technologies
Palatin Technologies Stock Down 3.9%
Palatin Technologies stock opened at $5.15 on Thursday. Palatin Technologies has a 1 year low of $4.51 and a 1 year high of $31.00.
Institutional Investors Weigh In On Palatin Technologies
An institutional investor recently bought a new stake in Palatin Technologies stock. State Street Corp acquired a new position in shares of Palatin Technologies (NASDAQ:PTN – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 14,000 shares of the company’s stock, valued at approximately $124,000. State Street Corp owned 0.79% of Palatin Technologies at the end of the most recent quarter. Institutional investors own 11.50% of the company’s stock.
Palatin Technologies Company Profile
Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications. The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
See Also
- Five stocks we like better than Palatin Technologies
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
